NCT03521726View on ClinicalTrials.gov

Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 11, 2018

Primary Completion Date

February 12, 2019

Study Completion Date

February 12, 2019

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

Amoxicillin

Twenty patients receive Intraluminal Amoxicillin eradication for H. pylori.

DRUG

Rabeprazole, Amoxicillin

Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole, Amoxicillin) for 14 days.

Trial Locations (1)

10449

Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan, Taipei

All Listed Sponsors
lead

Mackay Memorial Hospital

OTHER

NCT03521726 - Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection | Biotech Hunter | Biotech Hunter